Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria | Zendy

Xavier Hanoulle | Zendy; JeanMichel Wieruszeski | Zendy; Pierre RousselotPailley | Zendy; Isabelle Landrieu | Zendy; Camille Locht | Zendy; Guy Lippens | Zendy; Alain R. Baulard | Zendy

Open Access

Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria

Author(s) -

Xavier Hanoulle,

JeanMichel Wieruszeski,

Pierre RousselotPailley,

Isabelle Landrieu,

Camille Locht,

Guy Lippens,

Alain R. Baulard

Publication year - 2006

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl332

Subject(s) - ethionamide , prodrug , antimycobacterial , chemistry , rifabutin , metabolite , mycobacterium tuberculosis , pharmacology , microbiology and biotechnology , biochemistry , antibiotics , ethambutol , biology , tuberculosis , medicine , rifampicin , clarithromycin , pathology

Ethionamide is one of the most widely used drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB). Like isoniazid, and pyrazinamide, ethionamide is a prodrug that needs to be activated by a mycobacterial enzyme. Activation pathways of prodrugs are generally problematic to uncover as they produce intermediates potentially difficult to characterize, to purify and that might prove unstable outside of their cellular context.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research